Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
NCT02532218
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
176
Enrollment
INDUSTRY
Sponsor class
Conditions
Hyperlipidemia
Interventions
DRUG:
ARI-3037MO
Sponsor
Arisaph Pharmaceuticals Inc